Shares in Cancer therapy focused firm DelMar Pharmaceuticals (NASDAQ: DMPI) added over 19% to $2.21 in New York as it received the green light to conduct a pivotal Phase 3 study.
DelMar's VAL-083 STAR-3 GBM trial is a randomized, controlled clinical trial in patients with glioblastoma multiforme (GBM) whose disease has progressed following prior treatment with temozolomide and bevacizumab.
Enrollment to open..
Chairman and chief executive Jeffrey Bacha said: "We are pleased to remain on track to open enrollment in this trial at leading centers in the United States.
"Based on our research, we believe that VAL-083 offers significant potential as a new therapy for GBM patients who currently have no viable treatment options."
Up to 180 patients..
Up to 180 eligible patients will be randomized at 25 centers in the United States to receive either the investigational drug (VAL-083) or "investigator's choice salvage therapy" as a contemporaneous control.
Glioblastoma (GBM) is the most common and aggressive primary brain cancer.
Current standard of care includes surgery, radiation and treatment with temozolomide (TMZ), however nearly all tumors recur and the prognosis for the recurrent form of the disease is dismal.